Disease Landscape and Forecast 인사이트
종합적인 시장 정보와 실행 가능한 인사이트를 통해 장기적인 질병 전략을 최적화하세요.
Rheumatoid Arthritis | Emerging Therapies | Olumiant (baricitinib) | US | Wave 3 | 2019
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after the launch of Pfizer’s Jak inhibitor, Xeljanz…
Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Trigeminal Neuralgia (US) |2018
Trigeminal neuralgia (TGN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve…